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Abstract
Background: Airway inflammation in COPD can be measured using biomarkers such as induced
sputum and FeNO. This study set out to explore the heterogeneity of COPD using biomarkers of
airway and systemic inflammation and pulmonary function by principal components analysis (PCA).
Subjects and Methods: In 127 COPD patients (mean FEV1 61%), pulmonary function, FeNO,
plasma CRP and TNF-α, sputum differential cell counts and sputum IL8 (pg/ml) were measured.
Principal components analysis as well as multivariate analysis was performed.
Results: PCA identified four main components (% variance): (1) sputum neutrophil cell count and
supernatant IL8 and plasma TNF-α (20.2%), (2) Sputum eosinophils % and FeNO (18.2%), (3)
Bronchodilator reversibility, FEV1 and IC (15.1%) and (4) CRP (11.4%). These results were
confirmed by linear regression multivariate analyses which showed strong associations between the
variables within components 1 and 2.
Conclusion:  COPD is a multi dimensional disease. Unrelated components of disease were
identified, including neutrophilic airway inflammation which was associated with systemic
inflammation, and sputum eosinophils which were related to increased FeNO. We confirm
dissociation between airway inflammation and lung function in this cohort of patients.
Background
Chronic obstructive pulmonary disease (COPD) is an
inflammatory airway disease characterised by poorly
reversible airway obstruction. In fact, COPD can be
viewed as an umbrella term that encompasses a range of
pulmonary and systemic manifestations. COPD severity is
graded by forced expiratory volume in 1 second (FEV1)
[1], but this grading does not recognise the range of
pathophysiological abnormalities that may be present in
this heterogeneous condition. There is currently much
interest in improving the phenotypic description of
COPD by the use of biomarkers that allow distinct sub-
groups of patients with different prognosis or response to
therapy to be identified [2].
Induced sputum is a safe and non-invasive method for
studying biomarkers of airway inflammation in COPD
patients, neutrophil [3] and eosinophil [4] numbers being
the most valuable measures at present. An alternative
biomarker is nitric oxide (NO), which is synthesized from
L-arginine by nitric oxide synthase (NOS) enzymes and
can be measured in exhaled breath (FeNO). FeNO (frac-
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tional exhaled nitric oxide) has not become widely used as
a biomarker in COPD patients as it is reduced by current
cigarette smoking [5] and can therefore mainly be used in
ex-smokers [6,7] and subjects with unstable disease [8].
Biomarkers of airway inflammation, such as induced spu-
tum and FeNO, clearly have the potential to define sub-
groups of COPD patients with different characteristics. In
order to use these biomarkers to enhance phenotype
description, it would be important to know other clinical
characteristics associated with these biomarkers. For
example, patients with COPD have increased levels of sys-
temic inflammation [9,10], with CRP levels being associ-
ated with increased mortality [11], possibly through
cardiovascular disease [10]. Such associations between
airway and systemic inflammation may point towards
specific pathophysiological mechanisms that contribute
to disease characteristics.
Multivariate modelling overcomes has been used to test
pre-determined hypotheses concerning the relationships
between biomarkers and other measurements in COPD
[12,13]. An alternative strategy is to use methods that gen-
erate hypotheses rather than test pre-determined hypoth-
eses. Exploratory factor analysis [14,15] is a hypothesis
generating method that identifies groups of associated
parameters into factors that are responsible for disease
heterogeneity. This approach has previously been used in
COPD to demonstrate dissociation between airway
inflammation and pulmonary function [16]. Principal
components analysis (PCA) is the commonest form of
factor analysis and reduces a large number of variables to
a much smaller number of components, explaining the
variability within the data set. These components repre-
sent latent processes which cannot be directly measured.
In the context of COPD, components may represent the
pathophysiological processes responsible for disease het-
erogeneity.
We report the use of PCA to explore the heterogeneity in
markers of airway and systemic inflammation and pulmo-
nary function in a cohort of subjects with COPD. The pri-
mary aim of this study was to identify components
representative of the different pathophysiological proc-
esses and hence generate hypothesis concerning COPD
phenotype description. We also used traditional multivar-
iate modelling to test the predetermined hypothesis that
the non-invasive airway biomarkers studied were associ-
ated with other disease parameters.
Methods
Subjects
127 COPD patients (44 smokers and 83 ex-smokers) diag-
nosed according to current guidelines [1] with a signifi-
cant smoking history (> 10 pack years), and spirometric
measurements of post bronchodilator forced expiratory
volume in 1 second (FEV1) < 80% and FEV1/forced vital
capacity (FVC) < 0.7 were recruited. Patients were
recruited from primary care by media advertising. Only
subjects who had negative skin prick tests to three aller-
gens (house dust mite, grass pollen and cat hair; ALK
Abello; Denmark) were included and patients with a clin-
ical history of asthma or atopy were excluded. Additional
exclusion criteria were a respiratory tract infection or exac-
erbation of COPD in the preceding six weeks. The demog-
raphy of all participants is shown in Table 1. Written and
informed consent was obtained and the local ethics com-
mittee approved the study.
Study design
The following procedures were performed on a single
study visit in order: measurement of FeNO, spirometry,
plethysmography, sputum induction and peripheral
blood sampling. Inhaled corticosteroids were withheld
for 12 hours prior to the study visit.
FeNO
Subjects were asked to abstain from food and caffeine for
two hours, nitrate enriched foods for 24 hours, smoking
for six hours, and alcohol for twelve hours prior to the
measurement of FeNO using a Niox chemiluminescence
on-line analyser (Aerocrine, Solna, Sweden). The smoking
history was checked by questioning before FeNO measure-
Table 1: Subject demography and descriptive data of variables
Variable Mean (SD)
Age (years) 64.6 (7.6)
Gender (M/F) 80/47
ICS use (yes/no) 73/54
ICS daily dosage (microgrammes)$ 990.4 (695.2)
Smoking pack years 47 (23)
IC (litres) 2.2 (0.6)
FEV1 (% Predicted) 61.2 (15.0)
Reversibility (%) 6.1 (5.7)
BMI 27 (0.5)
FeNO (ppb) 15.9 (13.8–18.3)*
Sputum IL8 (pg/ml) 641.3 (536.5–766.6)*
CRP (mg/ml) 3.1 (2.5–3.8)*
TNFα (pg/ml) 1.6 (1.5–1.8)*
Sputum TCC (×106) 4.8 (3.5–6.2)*
Sputum Neutrophil TCC (×106) 4.2 (2.8–5.5)*
Sputum Eosinophil TCC (×106) 0.2 (0.1–0.3)*
Sputum Neutrophil % 76.9 (73.5–80.3)*
Sputum Eosinophil % 6.2 (3.9–8.6)*
*Geometric mean (95% confidence interval presented for variables 
that were log transformed.
ICS; inhaled corticosteroid, IC; inspiratory capacity, FEV1; forced 
expiratory volume in 1 second, BMI; body mass index, FeNO; fractional 
exhaled nitric oxide, CRP; C-Reactive Protein, TNFα tumour 
necrosis factor-alpha, TCC; total cell count.
$ Beclomethasone dipropionate equivalent ICS total daily dosage in 
73 ICS usersRespiratory Research 2009, 10:41 http://respiratory-research.com/content/10/1/41
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ments were commenced. After inhaling NO free air to
total lung capacity, subjects exhaled at a constant flow rate
against a resistor to collect the plateau NO concentration
at flow rate 50 ml/s (ATS guidelines). Three acceptable
readings were recorded according to the American Tho-
racic Society guidelines [17].
Pulmonary function
Maximum expiratory flow volume measurements were
performed in triplicate using the spirometry system on the
Masterscreen; we recorded the highest FEV1  and FVC.
Readings were repeated 15 minutes after 200 mcg Salbuta-
mol via spacer. Inspiratory capacity (IC) was measured in
a constant volume plethysmograph (Sensormedics Vmax
6200).
Induced sputum
Sputum was induced using 3%, 4% and 5% saline,
inhaled in sequence for 5 min via an ultrasonic nebuliser
(Ultraneb 2000, Medix, Harlow, UK). Sputum was
selected from the saliva, and processed with DTT as previ-
ously described [18]. Cytospin preparations were air
dried, fixed with methanol and stained with Rapi-diff (Tri-
angle, Skelmersdale, UK). Four hundred leukocytes were
counted and the results expressed as a percentage of the
total leucocyte count, and a total cell count (TCC).
Sputum supernatant cytokine analysis
Interleukin 8 (IL-8) was measured by enzyme linked sand-
wich immunoassay (ELISA) (R&D Systems Europe, Oxon,
UK) with a lower limit of detection of 15.625 pg/ml.
Plasma assays
Plasma was obtained from peripheral blood samples by
centrifugation at 2500 rpm and 4°C for 15 minutes.
Plasma was stored at -80°C until analysis. Tumour Necro-
sis Factor-alpha (TNF-α) was measured by high sensitivity
ELISA (Quantikine, R&D Systems Europe, Oxon, UK)
with a lower limit of detection of 0.5 pg/ml. C-reactive
protein (CRP) was measured by high sensitivity particle
enhanced immunonephelometry (Cardiophase; BN sys-
tems, Dade Behring, Newark, USA) with a lower limit of
detection of 0.175 mg/L.
Statistical analysis
All statistical analyses were performed using SPSS 13.0
(SPSS Inc, Chicago, Ill). The Kolmogorov Smirnov test
determined normality of data. Non-parametric data were
natural log transformed and presented as geometric
means and 95% confidence intervals. Statistical signifi-
cance was considered at p ≥ 0.05. PCA analysis was per-
formed as follows:
1. Variable selection
The following variables were included: FEV1  (% pre-
dicted), IC (L), reversibility (% predicted), FeNO (ppb),
CRP (mg/L), TNF-α (pg/ml), sputum TCC (×106), sputum
neutrophil TCC (×106) and eosinophil % and sputum IL8
(pg/ml). The PCA was not run with sputum neutrophil %
and eosinophil % as they are mathematically related.
Instead, neutrophil TCC was included as this reflects the
neutrophil load in the airways.
2. Component extraction
We interpreted only the loadings with an absolute value
greater than 0.4 (which explains around 16% of the vari-
ance by the variable) [15]. Missing data cases were
excluded pair wise rather than list wise to maintain suffi-
cient numbers for the analysis.
3. Rotation
An oblique rotation was chosen based on the implausibil-
ity of independent components assumed by orthogonal
rotations. However, both oblique promax and orthogonal
varimax rotations were examined and produced extremely
similar components demonstrating stability of the com-
ponents.
4. Component Validity
Component scores for each patient were calculated using
the regression method. To validate the components, a
MANOVA (multivariate analysis of variance) was run with
the PCA scores as outcome variables and the demographic
details (age, gender, smoking status, smoking pack years,
BMI and inhaled steroid usage) as the predictors. If the
predictor terms were significantly related to the PCA com-
ponents according to Pillai's test then individual associa-
tions between predictors and components were examined
using specific post hoc tests.
Multivariate analysis
Univariate analysis was initially performed between all
variables. Those variables that were associated with more
than one other variable (P < 0.2) were entered into multi-
variate regression models. This allowed variables that
were independent predictors of the variables after adjust-
ing for potential confounding variables to be determined.
Measurements of airway inflammation (induced sputum
measurements including cell counts and percentages and
FeNO) were the dependent variables. Linear regression was
used for continuous variables. Where 2 or more inde-
pendent predictors were found, analysis of the interaction
between these predictors was performed.
Results
Figure 1 shows that of the 127 patients, 10 patients could
not perform FeNO adequately, 21 patients did not have
blood taken for analysis, and 92 produced adequate spu-
tum for analysis. There was no difference in pulmonary
function or blood biomarker measurements between the
patients who could and could not perform these measure-
ments. All patients were included in the analysis, with 70Respiratory Research 2009, 10:41 http://respiratory-research.com/content/10/1/41
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patients having a complete dataset with all variables. The
post bronchodilator FEV1 range for these COPD patients
was 17.9 to 79.6%. 98 of the 127 patients had moderate
COPD (GOLD stage II), while 22 had severe disease
(GOLD stage III) and 4 very severe disease (GOLD stage
IV).
Component generation
9 variables were included in the PCA (Kaiser-Meyer-Olkin
measure of sampling adequacy 0.5, Bartlett's Test of
sphericity < 0.0001). 4 components with eigenvalues > 1
were identified with a subsequent break in the scree plot
(Figure 2). These 4 components explained 64.9 % of the
variance between patients. The variables loading > 0.5 are
shown in Table 2, along with the proportion of variance
explained by each component.
Component (1) consisted of measurements corresponding
to neutrophilic airway inflammation (sputum neutrophil
cell count and sputum supernatant IL8) and systemic
inflammation (plasma TNF-α) explaining the most varia-
bility in the data (20.2%). This was followed by sputum
eosinophils and FeNO which contributed to a similar pro-
portion of the variance (18%), component (2). A compo-
nent was also formed of bronchodilator reversibility, FEV1
and IC measurements (15% of variance), component (3).
CRP levels contributed 11% of the variability, solely rep-
resenting component (4). The components remained unal-
tered when varimax rotation was applied instead of
promax and even when the solution was unrotated
Correlations between components
The correlations between the 4 components from the pro-
max solution were weak (Table 3) showing that all the
components were distinct from one another.
MANOVA; Relationships between components and clinical 
data
Table 4 summarises the significant predictors of the com-
ponents in the MANOVA. The variables in component 2
were associated with age, current smoking status and gen-
der. Component 4 (CRP level) was associated with
inhaled corticosteroid use and pack year history.
Multivariate analysis
Different multivariate models were used to determine
independent predictors of the following airway inflam-
mation measurements; sputum total cell count, sputum
neutrophil and eosinophil cell count and percentage dif-
ferential and supernatant IL-8 levels (Table 5). Plasma
TNF-α levels were significantly associated with sputum
neutrophil cell count and supernatant IL-8 levels, and
there were significant associations between sputum neu-
trophils and supernatant IL-8 levels. There were strong
and highly significant associations (p < 0.0001) between
FeNO and sputum eosinophils, regardless of whether the
data was expressed as percentage differential or cell count.
Reversibility was associated with eosinophil percentage.
Smoking and gender were independent predictors of FeNO
levels, with lower levels seen in COPD smokers and
women. Neutrophil percentage was negatively correlated
with FeNO levels and reversibility.
Discussion
The primary aim of this study was to generate hypotheses
about COPD phenotype description and disease mecha-
nisms by exploring the variability in markers of inflam-
mation and lung function using PCA. This analysis
suggests that COPD is a truly multi-dimensional disease.
PCA identified four main components, each explaining
similar amounts of the variance (between 10 and 20%).
The first two components represented neutrophilic and
eosinophilic inflammation, explaining 20.2% and 18.2%
of the variance respectively. Lung function parameters
formed a separate component, comprising measures of
airflow obstruction and reversibility. CRP also formed a
separate component. Some hypotheses about disease
mechanisms can be generated from this analysis; compo-
nent 1 suggests that the profile of neutrophilic airway
inflammation is associated with systemic inflammation,
and component 2 suggests that patients with sputum eosi-
nophilia, which is associated with increased corticoster-
oid responsiveness [4] also have increased FeNO levels.
Importantly, PCA indicates that these are distinct compo-
nents of disease that could be used for patient phenotyp-
ing [19]. Correlations between the components were
weak despite the use of a Promax rotation. To validate the
PCA components, we performed multivariate modelling,
which confirmed our PCA findings.
The main limitation of any PCA is the selection of varia-
bles included. This analysis has focused on a selection of
Flow chart showing the total number of patients who were  able to perform all measurements and those who were una- ble to complete certain measurements Figure 1
Flow chart showing the total number of patients who 
were able to perform all measurements and those 
who were unable to complete certain measure-
ments.
127 patients
117 with FeNO data  106 with CRP 
and TNF data 
92 with sputum 
data for cell counts 
and IL8 assay 
70 patients with 
complete datasets for 
all listed variables Respiratory Research 2009, 10:41 http://respiratory-research.com/content/10/1/41
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well studied markers of airway [3,4] and systemic inflam-
mation [13,20,21] as well as pulmonary function, by
which COPD is classically defined [1]. Other important
biomarkers of COPD pathophysiology, explaining further
disease heterogeneity may not have been included. Never-
theless, our study shows the potential utility of PCA, and
further studies using other biomarkers of inflammation or
clinical measurements would be of interest.
The results of PCA are critically dependent on the selec-
tion of subjects. If particular subgroups of patients are
included or excluded from the study, the sources of varia-
tion in the dataset will be affected. A common issue in
studies of airway sampling in COPD patients, either by
induced sputum or FeNO, is that not all patients can com-
plete each measurement [16]. We used a well validated
approach to this issue, excluding cases pairwise where
data was missing [14], so that all of the 92 patients with
induced sputum data and 117 patients with FeNO data
could be analysed where possible e.g. all of these data
could be analysed against pulmonary function. We did
not exclude patients who could not perform certain anal-
ysis, as this may have introduced a bias into the dataset;
e.g. certain patient phenotypes may produce less sputum
than others, and by excluding such patients any such a
phenotype would be poorly represented in the data set.
Factor analysis/PCA has been rarely used in COPD [16,22-
25]. The sample for the currents study compares very
favourably with these studies, which have often enrolled
less than 100 subjects [22-25]. Indeed, even if we
accounted for the incomplete measurements in the cur-
rent study, the sample size of patients with a "complete
dataset" (n = 70), is still larger than the enrolled sample
size of some of these studies [16,22-25].
Recently, factor analysis has been used by Lapperre et al
[16] in 114 COPD patients to generate hypothesis about
disease description using many of the same parameters as
the current study, but importantly systemic inflammation
biomarkers were not investigated. A four factor solution
was reported, with the character of the components being
somewhat different to our findings. Firstly, a factor repre-
senting asthma like parameters (i.e. reversibility, bron-
chial hyper-reactivity and atopy) was identified. This may
be due to some extent to differences in subject selection,
as in our cohort subjects with asthma may have been
more rigorously excluded, as atopic subjects were not
recruited. Secondly, Lapperre et al reported a component
including sputum percentage neutrophils and eosi-
nophils, and that FeNO was not in the same component as
sputum eosinophils, which differs from our results.
Important methodological issues should be considered;
(a) Lappere et al used 2 different FeNO analysers, but it is
known that data from different analysers generates signif-
icantly different NO levels [26]. This could explain why
FeNO was in a distinct component, as associations with
other parameters were not possible as the absolute FeNO
values were actually mostly dependent on the type of ana-
lyser used rather than any patient characteristics (b)
Laperre et al included both sputum eosinophil and neu-
trophil % in the factor analysis, which together were
found to form a distinct component. However, there is a
mathematical relationship between these parameters (as
one increases, the other decreases). The impact on PCA
analysis is that the mathematical relationship between
sputum percentages will cause these parameters to be
associated within the same component, and may cause
associations with other parameters, such as FeNO, to be
overlooked. We used sputum total neutrophil cell count
and sputum eosinophil percentage in the PCA to avoid
this issue. Reassuringly, our PCA findings concerning
FeNO  and eosinophils were confirmed by multivariate
modelling showing a significant association between
these parameters.
The positive relationship between FeNO and sputum eosi-
nophils has been observed in a smaller COPD group [27]
but not by Siva et al [28] in 83 COPD patients. Again,
measurement methodology may give an explanation for
the lack of positive findings, as Siva et al used a flow rate
of 250 ml/s, which is well known to give very low FeNO
readings, particularly in COPD patients, and so may not
be able to discriminate between patients.
Component 1 suggests that sputum neutrophils and the
neutrophil chemoattractant IL-8 describe a distinct com-
ponent of disease that is associated with systemic inflam-
mation, measured by plasma TNFα levels. It is perhaps
surprising that the other systemic inflammation biomar-
ker that we measured, CRP, was not associated with air-
way neutrophils. CRP is a known marker of cardiovascular
Scree plot showing Eigenvalues for components with a refer- ence line at Eigenvalue of 1 Figure 2
Scree plot showing Eigenvalues for components with 
a reference line at Eigenvalue of 1.
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disease risk [29] and levels in COPD are associated with
mortality [11], leading to the hypothesis that CRP levels
are indicative of cardiovascular disease risk in COPD
patients. A possible explanation for our findings is that
neutrophilic airway inflammation is associated with some
systemic inflammation pathways, such as TNFα which is
known to be involved in muscle inflammation [20], but
not CRP which is an indicator of cardiovascular disease.
Inhaled corticosteroid use was associated with CRP levels;
this may be due to more severe patients with higher CRP
levels being prescribed inhaled corticosteroids. Inhaled
corticosteroid use was not associated with pulmonary
function (component 3); this may be viewed as a surpris-
ing finding as corticosteroids are used for patients with
lower FEV1 values who have exacerbations. The reason for
the lack of an association in the current study was proba-
bly that the range of FEV1 values was relatively narrow, as
most patients had moderate COPD (GOLD stage 2), and
that the inclusion of greater numbers of severe/very severe
patients would be needed to assess this relationship fur-
ther.
It has been reported that sputum neutrophil counts [30]
and IL-8 [31] levels are related to severity of airflow
obstruction and subsequent decline in FEV1 in COPD. Air-
way tissue immunohistochemistry studies clearly show
that mucosal inflammation is associated with lower FEV1
[32]. However, in agreement with the previous study by
Laperre et al we found dissociation between airway
inflammation and pulmonary function. This suggests that
luminal inflammation, sampled by induced sputum, is
not associated with FEV1. A strength of the current study
in coming to this conclusion is the sample size used, and
2 independent statistical analysis techniques. However, it
is possible that other population groups including more
patients with very severe COPD may generate different
results.
Our study population was composed of mainly GOLD
stage 2 "moderate" COPD patients, although 26 severe/
very severe patients were also recruited. This mix of
patients reflects our strategy of recruiting from primary
care. It would be of interest to repeat the current study
using more severe patients, perhaps recruited from hospi-
tal clinics, to observe whether the same or different results
are obtained.
We found that females with COPD had lower levels of
FeNO than males, which has been shown to be true in
healthy controls [33]. Similarly, the associations of FeNO
with age and with smoking that we observed have also
previously been reported [34].
In summary, this study provides insights into the dimen-
sions of COPD that can be described using non-invasive
biomarkers of airway inflammation and pulmonary func-
tion. Independent components representing different
types of airway inflammation, lung function and systemic
inflammation have been identified providing novel con-
cepts with regards to COPD pathophysiology. We hope








Sputum neutrophil TCC 0.72
Plasma TNFα 0.76
(2) Component 2 (18.2%)
Sputum eosinophil % 0.86
FeNO 0.85




(4) Component 4 (11.4%)
CRP 0.86
All variables shown load over 0.50 onto a single PCA component.
IC; inspiratory capacity, FEV1; forced expiratory volume in 1 second, 
BMI; body mass index, FeNO; fractional exhaled nitric oxide, CRP; C-
Reactive Protein, TNFα tumour necrosis factor-alpha, TCC; total cell 
count.
Table 3: Component Correlation Matrix
Component 1 2 3 4
1 1.000 .
2 .001 1.000
3 .029 .112 1.000
4 .246 -.078 -.020 1.000
Table 4: Summary of MANOVA showing significant predictors of 
the components; predictor variables included in the analysis 
were age, gender, ICS use, smoking status, smoking pack years 
and BMI
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that our results will provide an impetus to further explore
the usefulness of these components in guiding clinical
practice by assessing their ability to predict important fea-
tures of COPD such as prognosis, systemic manifestations
and treatment responses.
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NS NS P < 0.0001
R = 0.57
NS NS NS P = 0.01
R = 0.44




NS NS NS NS NS NS





Gender P = 0.04
R = 0.7
(lower in females)
NS NS NS NS NS NS
FEV1, IC, BMI, Bronchodilator reversibility, plasma CRP, ICS usage and smoking pack years did not predict any of the variables marking airway 
inflammation.
P and R values were determined by linear regression multivariate analysis.
NS : No significant association.
TNFα; tumour necrosis factor-alpha, TCC; total cell count.Publish with BioMed Central    and   every 
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